camizestrant
Coverage of camizestrant in the Nexus archive.
- STAT+: Kailera’s own ‘triple-G’ drug also looks very powerful
The FDA delayed a decision on AstraZeneca's breast cancer drug camizestrant due to advisory concerns over its trial design. Blackstone Life Sciences is investing $1.3 billion in Apogee Therapeutics for Phase 3 development of zumilokibart, a long-acting atopic dermatitis treatment. Kailera's experimental obesity drug, targeting three hormones, showed significant weight loss in a Phase 1 study.
- STAT+: Pharmalittle: We’re reading about an AstraZeneca breast cancer pill, an ADAP deal in Florida, and more
The FDA has extended the decision deadline for AstraZeneca's experimental breast cancer pill, camizestrant, to review additional data after an advisory panel raised concerns about a late-stage trial's design. Brazil approved the first generic version of Novo Nordisk's Ozempic (now Ozivy) by EMS, a pharmaceutical company, which plans to sell it at 30% lower cost.